12:00 AM
 | 
Jul 22, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Dovitinib lactate: Phase III data

Novartis disclosed in its 2Q13 earnings that an open-label, international Phase III trial in about 564 patients with metastatic RCC after failure of prior anti-angiogenic therapies showed that dovitinib missed the primary endpoint of improving PFS vs. Nexavar sorafenib. The...

Read the full 187 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >